Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

Articoli con TAG: cannabinoidi

Accertamenti tossicologici su sangue a seguito dell’applicazione dell’articolo 187 del Codice della Strada: uno studio retrospettivo nei territori di Milano e provincia
Toxicological investigations on blood for driving under the influence of drug of abuse: a retrospective study in Milan and districts
A. Masarin, C. Gechtman, S. Paccagnini, G.P. Gesu
<p>In Italy driving under the influence of drug of abuse (DRUID) is prosecuted since 1992.&nbsp;Controls are performed according to a two-step procedure: blood immunoscreening followed, in case of result&nbsp;positivity, by confirmation using a separative technique coupled to mass spectrometry. This study reports a two-year&nbsp;(2012-2014) retrospective review of blood analyses performed in this framework in our hospital. Over this period,&nbsp;1384 subjects [1170 (84.5%) were male, mean age 36.7 years] were controlled on request by the authorities of Traffic&nbsp;Police. 426 subjects (30,7%) were found positive to at least one drug. Among them, 212 were positive for cannabis,&nbsp;150 for cocaine and its metabolites, 24 for opiates, 16 for methadone and 9 for amphetamine-type stimulants. Out of&nbsp;the 212 subjects tested positive for cannabis, 141 had detectable levels of ????-9-tetrahydrocannabinol (THC) for&nbsp;engaging prosecution against the drivers. Blood THC concentrations were in the range between 2 38 &mu;g/L. Our&nbsp;results clearly illustrate the huge prominence of cannabis among substances involved in DRUID. According to our&nbsp;data, 9.9% of drivers found positive for cannabis and cocaine metabolites, probably no longer under the influence of&nbsp;drug of abuse at time they were driving, should be submitted to other investigations (e.g., on hair).</p>
Biochimica Clinica ; 39(3) 184-187
Contributi scientifici - Scientific Papers
 
Documento di consenso Gruppo di Studio di Farmacotossicologia Clinica e Doping SIBioC e Gruppo Tossicologi Forensi (GTFI). Modalità per lo svolgimento di indagini di laboratorio per la determinazione delle sostanze d’abuso
Consensus document of the Study Group on Clinical Pharmacotoxicology and Doping of Italian Society ofClinical Biochemistry and Italian Forensic Toxicologists Group (GTFI) – for laboratories involved in thedetermination of substances of abuse
<p>The greatest workload for the laboratories performing pharmacotoxicological tests remains the routine activity for detection and measurement, in different biological matrices, of psychotropic substances such as opiates, cocaine, cannabinoids, amphetamines, methadone, buprenorphine and ethyl alcohol. In addition to the investigations requested for clinical reasons, the requests to the pharmacotoxicological laboratories may also include medico-legal investigations, whose variety and complexity contributed to the adoption of personalized and extremely diverse operating modalities implemented in the Italian laboratories. The purpose of this document is to provide the Laboratories of the National Health Service in Italy that are planning to carry out or that already perform determination of drugs of abuse for medico-legal purposes, with recommendations at national level that take into account the &ldquo;good laboratory practices&rdquo; recognized at the international level in order to perform accurate and precise analytical tests so that they can meet the requirements necessary to provide a high quality and legally unassailable service.</p>
Biochimica Clinica ; 43(4) 449-452
Documenti SIBioC - SIBioC Documents